Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 50 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Oak Pharma from Oostkamp, company number BE0655792749, closed financial year 2025 with a result of € 48,250 after tax. For that financial year Oak Pharma recorded a gross margin of € 262,993 and equity of € 78,004. Compared with financial year 2024, the result moved from € 4,299 to € 48,250. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 78,004
▲ 162% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 48,250
▲ € 43,952 vs 2024
Profit after tax over the fiscal year.
€ 12,897
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 59,404.
Debts at end 2025
€ 65,218
▼ 13% vs 2024
Loans from banks and other lenders, long and short.
€ 99,175
▼ 57% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,092
▲ 13% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 38,316 | € 157,723 | € 159,842 | € 262,993 | ▲ 65% |
| Profit after taxes | € -55,588 | € 56,274 | € 4,299 | € 48,250 | ▲ € 43,952 |
| Equity | € -30,819 | € 25,455 | € 29,754 | € 78,004 | ▲ 162% |
| Total debts | € 851,333 | € 785,835 | € 725,244 | € 390,137 | ▼ 46% |
| Cash | € 9,606 | € 23,697 | € 64,766 | € 12,897 | ▼ 80% |
| Retained profit | € -49,419 | € 6,855 | € 11,154 | € 59,404 | ▲ € 48,250 |
| Bank debt | € 100,000 | € 37,271 | € 75,000 | € 65,218 | ▼ 13% |
| Balance sheet total | € 820,514 | € 811,291 | € 754,998 | € 468,141 | ▼ 38% |
| Employees (FTE) | 0.4 | - | - | - |
Key figures of Oak Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Oak Pharma?
What happened at Oak Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 48,250 (▲ € 43,952 vs 2024). Source: NBB ↗
- Rias Baixas BV became a director. NBB
- Manipuro BV became a director. NBB
- Melissa Hellebuyck became a director. NBB
- Corujo BV became a director. NBB
- New establishment in Oostkamp. KBO
- Start of the company according to the CBE. KBO
In short
From € 55,588 loss in 2022 to € 48,250 profit in 2025.
Paid € 21,786 in corporate taxes since 2022.
Best year ever: 2023, with € 56,274 profit.
A new publication or filing at Oak Pharma? We notify you, reason included.
Follow Oak PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Oak Pharma are Melissa Hellebuyck, Rias Baixas BV, Corujo BV and Manipuro BV. Rias Baixas BV is also behind KEYPHARM. Corujo BV is also behind VIGO, O.N.S. and KEYPHARM. Manipuro BV is also behind KEYPHARM.
Directors
According to the 2025 annual accounts
Melissa Hellebuyck
Director
since 2021
since 2021
since 2021
since 2021
Establishments
Establishment units
Physical locations of this company
Siemenslaan 11
8020 Oostkamp
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
GOOGLE-CLOUD-PLATFORM - Google LLC, US
Domain
Domain
oakpharma.eu
Registrar
Combell NV
Website info
Features
Security
Details
- Company number
- 0655.792.749
- VAT number
- BE 0655.792.749
- Registered office
- Siemenslaan 11, 8020 Oostkamp
- Names & denominations
- Oak Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 May 2016
- Peppol
- Active · Active since 29 Oct 2025
- Contact
- oakpharma.eu
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van farmaceutische grondstoffen
Holdings
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering